You are here

Article Text

Article menu

Download PDFPDF

Scientific Abstracts
POSTERS only
Vasculitis – large vessel vasculitis
POS0806 OPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS. A MULTICENTER REAL-LIFE STUDY OF 471 PATIENTS.
Free
  1. C. Álvarez-Reguera1,
  2. M. Calderón-Goercke1,
  3. J. Loricera1,
  4. C. Moriano2,
  5. S. Castañeda3,
  6. J. Narváez4,
  7. V. Aldasoro5,
  8. O. Maiz6,
  9. R. Melero7,
  10. I. Villa-Blanco8,
  11. P. Vela-Casasempere9,
  12. S. Romero-Yuste10,
  13. J. L. Callejas-Rubio11,
  14. E. De Miguel12,
  15. E. Galíndez-Agirregoikoa13,
  16. F. Sivera14,
  17. C. Fernández-López15,
  18. C. Galisteo16,
  19. I. Ferraz-Amaro17,
  20. J. Sanchez-Martin18,
  21. L. Sanchez-Bilbao18,
  22. J. L. Hernández Hernández19,
  23. M. Á. González-Gay1,
  24. R. Blanco1
  25. on behalf of Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group.
  1. 1Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain
  2. 2Complejo Asistencial Universitario de León, Rheumatology, León, Spain
  3. 3Hospital Universitario de La Princesa, Rheumatology, Madrid, Spain
  4. 4Hospital Universitario de Bellvitge, Rheumatology, Barcelona, Spain
  5. 5ComplejoHospitalario de Navarra, Rheumatology, Pamplona, Spain
  6. 6Hospital Universitario de Donostia, Rheumatology, San Sebastián, Spain
  7. 7Complexo Hospitalario Universitario de Vigo, Rheumatology, Vigo, Spain
  8. 8Hospital Sierrallana, Rheumatology, Torrelavega, Spain
  9. 9Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain
  10. 10Complexo Hospitalario Universitario de Pontevedra, Rheumatology, Pontevedra, Spain
  11. 11Hospital San Cecilio, Rheumatology, Granada, Spain
  12. 12Hospital La Paz, Madrid, Madrid, Spain
  13. 13Hospital Universitario Basurto, Rheumatology, Bilbao, Spain
  14. 14Hospital Universitario de Elda, Rheumatology, Elda, Spain
  15. 15Complexo Hospitalario Universitario de A Coruña, Rheumatology, A Coruña, Spain
  16. 16Hospital Parc Taulí, Rheumatology, Barcelona, Spain
  17. 17Complejo Hospitalario Universitario de Canarias, Rheumatology, San Cristóbal de la Laguna, Spain
  18. 18Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain
  19. 19Hospital Universitario Marqués de Valdecilla, Internal Medicine, Santander, Spain

Abstract

Background Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA) (1-4). There is general agreement on the initial and the standard maintenance dose of TCZ. However, information on duration and optimization of TCZ in GCA is really scarce.

Objectives Our aim was to assess the effectiveness and safety of TCZ therapy optimization in an unselected wide series of GCA in real-world clinical practice.

Methods Multicenter study on 471 patients with GCA who received TCZ therapy. Once complete remission was reached (n=231) TCZ was optimized in 125 patients. We compared patients in whom TCZ was optimized (TCZOPT group) or not (TCZNON-OPT group). Complete remission was defined as normalization of clinical and analytical (CRP and ESR) data. Optimization was done by decreasing the dose and/or prolonging the TCZ dosing interval progressively. We performed a comparison in effectiveness and safety parameters between optimized and non-optimized patients.

Results We evaluated 231 GCA patients treated with TCZ with complete remission. No demographic or laboratory data differences was observed at TCZ onset between both groups (Table 1). The mean prednisone dose was higher in the TCZNON-OPT group at TCZ onset. The first TCZ optimization was performed after a median [25-75th] follow-up of 12 [6-17] months.

View this table:
Table 1.

Main general features at TCZ onset of 231 GCA patients with prolonged remission.

The median prednisone dose at first TCZ optimization was 2.5 [0-5] mg/day. At the end of follow-up prolonged remission was observed in 78.2% of TCZOPT group compared with 66.7% in the TCZNON-OPT group (p= 0.001) (Figure 1). Seven (5.6%) of the 125 optimized cases relapsed. Serious adverse events were similar in both groups, while serious infections were more frequent in the TCZNON-OPT group (p=0.009).

Conclusion Once complete remission is reached in GCA patients under TCZ treatment, optimization of biologic may be performed. Based on our experience it could be performed by reducing the dose or by prolonging dosing interval of TCZ. It seems to be an effective and safe practice.

References [1]Calderón-Goercke M, et al. Semin Arthritis Rheum. 2019; 49: 126-135. PMID: 30655091

[2]Loricera J, et al. Clin Exp Rheumatol. 2016; 34: S44-53. PMID: 27050507

[3]Prieto-Peña D, et al. Ther Adv Musculoskelet Dis. 2021; 13: 1759720X211020917. PMID: 34211589

[4]Loricera J, et al. Int Immunopharmacol. 2015; 27: 213-9. PMID: 25828585

Figure

Disclosure of Interests Carmen Álvarez-Reguera: None declared, Monica Calderón-Goercke: None declared, J. Loricera: None declared, Clara Moriano: None declared, Santos Castañeda: None declared, J. Narváez: None declared, Vicente Aldasoro: None declared, Olga Maiz: None declared, Rafael Melero: None declared, Ignacio Villa-Blanco: None declared, Paloma Vela-Casasempere: None declared, Susana Romero-Yuste: None declared, Jose Luis Callejas-Rubio: None declared, Eugenio de Miguel: None declared, E. Galíndez-Agirregoikoa: None declared, Francisca Sivera: None declared, Carlos Fernández-López: None declared, Carles Galisteo: None declared, Iván Ferraz-Amaro: None declared, Julio Sanchez-Martin: None declared, Lara Sanchez-Bilbao: None declared, Jose Luis Hernández Hernández: None declared, Miguel Á. González-Gay Consultant of: Abbvie, Pfizer, Roche, Sanofi and MSD., Grant/research support from: Abbvie, MSD, Jansen and Roche., Ricardo Blanco Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD, Grant/research support from: Abbvie, MSD and Roche.

https://doi.org/10.1136/annrheumdis-2022-eular.3279

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.